TScan Therapeutics’ (TCRX) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research note issued to investors on Monday,RTT News reports. Wedbush currently has a $7.00 target price on the stock.

Several other equities research analysts have also recently commented on the company. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a report on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note on Wednesday, December 11th.

TScan Therapeutics Trading Up 1.3 %

Shares of TCRX stock opened at $3.01 on Monday. TScan Therapeutics has a 1 year low of $2.60 and a 1 year high of $9.69. The firm has a market capitalization of $160.65 million, a PE ratio of -2.84 and a beta of 0.79. The stock has a fifty day moving average of $4.57 and a two-hundred day moving average of $5.64. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $1.05 million during the quarter, compared to analyst estimates of $2.86 million. As a group, research analysts expect that TScan Therapeutics will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TCRX. Bank of New York Mellon Corp acquired a new position in shares of TScan Therapeutics in the 2nd quarter worth $682,000. Rhumbline Advisers purchased a new position in TScan Therapeutics in the 2nd quarter worth about $274,000. American Century Companies Inc. raised its holdings in TScan Therapeutics by 48.9% during the 2nd quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock worth $278,000 after buying an additional 15,596 shares during the period. Cornercap Investment Counsel Inc. acquired a new stake in TScan Therapeutics during the 2nd quarter worth about $134,000. Finally, Brown Brothers Harriman & Co. acquired a new position in shares of TScan Therapeutics in the second quarter worth about $445,000. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.